Indian Journal of Public Health Research & Development

IL-35 is an inhibitory cytokine, produced by Treg cells, smooth muscle cells, monocytes and vascular endothelial cells and has multiple functions to produce various phenotypic features. The aim of current study was to investigate the role of serum IL-35 concentration and other clinical parameters in allergic asthma patients and the role of treatment with corticosteroids on IL-35 concentration.

Clinical samples were obtained with informed consent from 54 allergic asthma patients (32 with treatment and 22 without treatment), 14 patients with Helicobacter pylori (H. pylori) infection and 22 healthy controls. The serum IL-35 has been detected according to the manufacturer's instruction with commercial human IL-35 ELISA Kit (My biosource, USA). Results: The mean concentration of plasma IL-35 in allergic asthma patients with treatment, allergic asthma patients without treatment, healthy control, and H. pylori patients, were 35.34, 71.4, 94.5 and 68.1pg/ml, respectively, and the highest concentrations were 104.62, 310.3, 241.3, and 229.1pg/ml, the lowest concentrations were 9.10, 11.6, 29.1, and 19.3pg/ml, respectively, and no significant correlations were found between IL-35 levels and total serum IgE levels, white blood cell count, and the percentage of eosinophils count in two groups of patients.

This study supported previous studies in that serum IL-35 level is reduced in allergic asthma patients.